Nugliptin M 500 Tablet is a combination oral antidiabetic medication containing Metformin 500 mg and Vildagliptin 50 mg, indicated for the management of type 2 diabetes mellitus. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production, enhancing insulin sensitivity, and improving peripheral glucose uptake and utilization. Vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, enhances the incretin system by preventing the degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), thereby increasing insulin secretion and decreasing glucagon release in a glucose-dependent manner. The combination therapy offers complementary mechanisms that improve glycemic control more effectively than monotherapy. Nugliptin M 500 is typically prescribed as part of a comprehensive diabetes management plan, including diet and exercise. It is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, severe renal impairment, or hypersensitivity to its components. Common adverse effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, with rare occurrences of hypoglycemia. Regular monitoring of blood glucose levels and renal function is recommended during therapy. Nugliptin M 500 should be used under medical supervision to optimize therapeutic outcomes and minimize potential risks.